Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives $40.89 Consensus Price Target from Analysts

Posted by on May 17th, 2026

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) have been given an average rating of “Hold” by the eleven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $40.8889.

Several research analysts recently issued reports on HRMY shares. Deutsche Bank Aktiengesellschaft cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price target for the company. in a report on Monday, February 23rd. Needham & Company LLC cut their price target on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Truist Financial increased their price target on shares of Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Zacks Research raised shares of Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. Finally, UBS Group cut their price target on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th.

Get Our Latest Analysis on Harmony Biosciences

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its holdings in Harmony Biosciences by 13.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company’s stock valued at $58,157,000 after buying an additional 245,784 shares in the last quarter. SG Americas Securities LLC increased its holdings in Harmony Biosciences by 109.9% in the first quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock valued at $56,529,000 after buying an additional 1,056,507 shares in the last quarter. American Century Companies Inc. increased its holdings in Harmony Biosciences by 11.2% in the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock valued at $46,013,000 after buying an additional 168,145 shares in the last quarter. State Street Corp increased its holdings in Harmony Biosciences by 0.5% in the fourth quarter. State Street Corp now owns 1,661,850 shares of the company’s stock valued at $62,186,000 after buying an additional 8,246 shares in the last quarter. Finally, LSV Asset Management increased its holdings in Harmony Biosciences by 3.9% in the fourth quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock valued at $62,008,000 after buying an additional 62,200 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $30.09 on Tuesday. The company has a 50-day simple moving average of $29.24 and a 200-day simple moving average of $33.12. Harmony Biosciences has a one year low of $25.52 and a one year high of $40.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 0.20 and a beta of 0.97.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The business had revenue of $215.39 million during the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. Harmony Biosciences’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.78 earnings per share. On average, analysts predict that Harmony Biosciences will post 3.34 EPS for the current year.

Harmony Biosciences Company Profile

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.

Featured Stories

Analyst Recommendations for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.